Literature DB >> 28289935

Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis.

Soenke Langner1, Marie-Luise Kromrey2, Jens-Peter Kuehn2,3, Matthias Grothe4, Martin Domin5.   

Abstract

OBJECTIVES: To identify a possible association between repeated intravenous administration of gadobutrol and increased signal intensity in the grey and white matter using voxel-based whole-brain analysis.
METHODS: In this retrospective single-centre study, 217 patients with a clinically isolated syndrome underwent baseline brain magnetic resonance imaging and at least one annual follow-up examination with intravenous administration of 0.1 mmol/kg body weight of gadobutrol. Using the "Diffeomorphic Anatomical Registration using Exponentiated Lie algebra" (DARTEL) normalisation process, tissue templates for grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) were calculated, as were GM-CSF and WM-CSF ratios. Voxel-based whole-brain analysis was used to calculate the signal intensity for each voxel in each data set. Paired t-test was applied to test differences to baseline MRI for significance.
RESULTS: Voxel-based whole-brain analysis demonstrated no significant changes in signal intensity of grey and white matter after up to five gadobutrol administrations. There was no significant change in GM-CSF and grey WM-CSF ratios.
CONCLUSION: Voxel-based whole-brain analysis did not demonstrate increased signal intensity of GM and WM on unenhanced T1-weighted images after repeated gadobutrol administration. The molecular structure of gadolinium-based contrast agent preparations may be an essential factor causing SI increase on unenhanced T1-weighted images. KEY POINTS: • Repeated administration of gadobutrol does not lead to increased signal intensity. • Voxel-based whole-brain analysis allows assessment of subtle changes in signal intensity. • Macrocyclic contrast agents in a proven dosage are safe.

Entities:  

Keywords:  Brain; Contrast media; Gadolinium; MRI; Multiple sclerosis

Mesh:

Substances:

Year:  2017        PMID: 28289935     DOI: 10.1007/s00330-017-4777-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  30 in total

1.  Improving lesion-symptom mapping.

Authors:  Chris Rorden; Hans-Otto Karnath; Leonardo Bonilha
Journal:  J Cogn Neurosci       Date:  2007-07       Impact factor: 3.225

2.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Radiology       Date:  2015-04-06       Impact factor: 11.105

3.  In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents.

Authors:  Enrico Tedeschi; Giuseppe Palma; Antonietta Canna; Sirio Cocozza; Carmela Russo; Pasquale Borrelli; Roberta Lanzillo; Valentina Angelini; Emanuela Postiglione; Vincenzo Brescia Morra; Marco Salvatore; Arturo Brunetti; Mario Quarantelli
Journal:  Eur Radiol       Date:  2016-02-23       Impact factor: 5.315

4.  Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy.

Authors:  Carlo Cosimo Quattrocchi; Carlo Augusto Mallio; Yuri Errante; Vincenzo Cirimele; Luciano Carideo; Antonella Ax; Bruno Beomonte Zobel
Journal:  Invest Radiol       Date:  2015-07       Impact factor: 6.016

5.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

6.  Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.

Authors:  Nozomu Murata; Luis F Gonzalez-Cuyar; Kiyoko Murata; Corinne Fligner; Russell Dills; Daniel Hippe; Kenneth R Maravilla
Journal:  Invest Radiol       Date:  2016-07       Impact factor: 6.016

7.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Authors:  Marc Port; Jean-Marc Idée; Christelle Medina; Caroline Robic; Monique Sabatou; Claire Corot
Journal:  Biometals       Date:  2008-03-15       Impact factor: 2.949

8.  Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.

Authors:  Gregory W White; Wendell A Gibby; Michael F Tweedle
Journal:  Invest Radiol       Date:  2006-03       Impact factor: 6.016

9.  High-Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images: Evaluation of the Macrocyclic Gadolinium-Based Contrast Agent Gadobutrol.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Johanna Hepp; Philipp Kickingereder; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Invest Radiol       Date:  2015-12       Impact factor: 6.016

10.  Extent of Signal Hyperintensity on Unenhanced T1-weighted Brain MR Images after More than 35 Administrations of Linear Gadolinium-based Contrast Agents.

Authors:  Yang Zhang; Yan Cao; George L Shih; Elizabeth M Hecht; Martin R Prince
Journal:  Radiology       Date:  2016-08-11       Impact factor: 11.105

View more
  5 in total

Review 1.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

Review 2.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

3.  Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Authors:  Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki
Journal:  Neurology       Date:  2019-07-08       Impact factor: 11.800

Review 4.  Gadobutrol in India-A Comprehensive Review of Safety and Efficacy.

Authors:  Jan Endrikat; Nicoletta Anzalone
Journal:  Magn Reson Insights       Date:  2017-09-11

5.  T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter.

Authors:  Peter Kelemen; Jamila Alaoui; Dominik Sieron; Andrew Chan; Christian P Kamm; Mirjam R Heldner; Jan Gralla; Roland Wiest; Rajeev K Verma
Journal:  Sci Rep       Date:  2018-11-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.